Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Axsome Therapeutics, Inc.
< Previous
1
2
Next >
Axsome Therapeutics Recognizes May as Mental Health Awareness Month
May 01, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
April 15, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
April 10, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
April 01, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
March 25, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
March 25, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
March 19, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
March 05, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
February 27, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 20, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20
January 23, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
January 04, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting
December 11, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today
December 07, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7
November 22, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference
November 21, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 06, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics and the Global Alzheimer’s Disease Community Come Together in Raising Support for the Millions Affected by This Illness During Alzheimer’s Disease Awareness Month 2023
November 02, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics to Present at Upcoming Investor Conferences
October 31, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Presents Results of the ACCORD trial of AXS-05 in Alzheimer’s Disease Agitation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Conference
October 24, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors
October 11, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics to Report Third Quarter 2023 Financial Results on November 6
October 10, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Joins the National Alliance on Mental Illness and Others Advocating for the Importance of Mental Health on Mental Illness Awareness Week
October 02, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Joins the Global Narcolepsy Community in Raising Awareness on World Narcolepsy Day
September 21, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Highlights Commitment to Innovating Treatments for Mental Health Conditions with Presentations at Psych Congress 2023
September 07, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics to Present at Three Upcoming Investor Conferences
September 05, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
August 07, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics to Report Second Quarter 2023 Financial Results on August 7
July 12, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults
July 07, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common Stock
June 30, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.